Table 1.

Summary of the clinicopathological characteristics of the squamous cell carcinoma and adenocarcinoma cases examined for EZH2 expression

Squamous cell carcinoma (N = 221)Adenocarcinoma (N = 320)
FeaturesCategoriesN (%)N (%)
SexFemale90 (40.7)177 (55.3)
Male131 (59.3)143 (44.7)
RaceCaucasian204 (92.3)288 (90.0)
Others17 (7.7)32 (10.0)
Smoking statusNever4 (1.8)54 (16.9)
Former114 (51.6)142 (44.4)
Current103 (46.6)124 (38.8)
T stage (IASLC)T164 (29.0)124 (38.8)
T2114 (51.6)157 (49.1)
T333 (14.9)32 (10.0)
T410 (4.5)7 (2.2)
N stage (IASLC)N0143 (64.7)237 (74.1)
N158 (26.2)51 (15.9)
N220 (9.1)32 (10.0)
TNM stage (IASLC)I102 (46.2)203 (63.4)
II80 (36.2)74 (23.1)
III39 (17.6)43 (13.4)
Adjuvant therapyNo162 (73.4)230 (71.9)
Yes59 (26.7)90 (28.1)
Vital statusAlive86 (38.9)177 (55.3)
Dead135 (61.1)143 (44.7)
Recurrence statusNo141 (63.8)205 (64.1)
Yes80 (36.2)115 (35.9)

Age median: SCC, 69.0 years; adenocarcinoma, 66.3 years.

Tumor size median: SCC, 3.5 cm; adenocarcinoma, 2.7 cm.